
Keywords: argatroban; danaparoid; fondaparinux; heparin; heparin-induced thrombocytopenia; lepirudin; EIA+/EIAâ; positive/negative platelet factor 4-dependent enzyme immunoassay; HIPA; heparin-induced platelet activation assay; HIPA+/HIPAâ; heparin-induced plat